WO2017142325A1 - 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 - Google Patents
단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 Download PDFInfo
- Publication number
- WO2017142325A1 WO2017142325A1 PCT/KR2017/001715 KR2017001715W WO2017142325A1 WO 2017142325 A1 WO2017142325 A1 WO 2017142325A1 KR 2017001715 W KR2017001715 W KR 2017001715W WO 2017142325 A1 WO2017142325 A1 WO 2017142325A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbonyl
- ethynyl
- carboxamide
- piperidin
- Prior art date
Links
- BCNLOZHNQGKAGY-AWEZNQCLSA-N CC[n]1ncc(C#Cc2cc(NC(N)=O)c(C(N[C@@H]3CNCCCC3)=O)[s]2)c1 Chemical compound CC[n]1ncc(C#Cc2cc(NC(N)=O)c(C(N[C@@H]3CNCCCC3)=O)[s]2)c1 BCNLOZHNQGKAGY-AWEZNQCLSA-N 0.000 description 1
- AZNNQAQQXWGQBN-UHFFFAOYSA-N C[n]1ncc(CCc2cc(NC(N)=O)c(C(NC3CNCC3)=O)[s]2)c1[F]C(C(O)=O)(F)F Chemical compound C[n]1ncc(CCc2cc(NC(N)=O)c(C(NC3CNCC3)=O)[s]2)c1[F]C(C(O)=O)(F)F AZNNQAQQXWGQBN-UHFFFAOYSA-N 0.000 description 1
- RMRVMRUTIURYAC-UHFFFAOYSA-N NC(C(S(C1CCNCCC1)C(CCc1cc(F)ccc1)=C1)=C1NC=O)=O Chemical compound NC(C(S(C1CCNCCC1)C(CCc1cc(F)ccc1)=C1)=C1NC=O)=O RMRVMRUTIURYAC-UHFFFAOYSA-N 0.000 description 1
- ULVAGWVTXBTFRN-AWEZNQCLSA-N NC(Nc1c(C(N[C@@H]2CNCCC2)=O)[s]c(C#Cc2cc(F)ccc2)c1)=O Chemical compound NC(Nc1c(C(N[C@@H]2CNCCC2)=O)[s]c(C#Cc2cc(F)ccc2)c1)=O ULVAGWVTXBTFRN-AWEZNQCLSA-N 0.000 description 1
- KTHXDSCIGURMOL-LBPRGKRZSA-N NC(Nc1c(C(N[C@@H]2CNCCC2)=O)[s]c(C#Cc2n[nH]c3c2cccc3)c1)=O Chemical compound NC(Nc1c(C(N[C@@H]2CNCCC2)=O)[s]c(C#Cc2n[nH]c3c2cccc3)c1)=O KTHXDSCIGURMOL-LBPRGKRZSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
- C07D333/10—Thiophene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a novel 2,3,5-substituted thiophene compound having protein kinase inhibitory activity, an anticancer agent comprising the compound as an active ingredient, and a method for preparing the compound.
- Protein kinases are enzymes that catalyze the phosphorylation of hydroxy groups located at tyrosine, serine and threonine residues of proteins and play an important role in the growth factor signal transduction that causes cell growth, differentiation and proliferation.
- the signaling system in vivo should be smoothly turned on and off.
- mutation or overexpression of certain protein kinases disrupts normal cellular signaling systems (mainly in vivo), leading to a variety of diseases, including cancer, inflammation, metabolic diseases, and brain diseases.
- Representative protein kinases that cause abnormal cell growth diseases include Raf, KDR, Fms, Tie2, SAPK2a, Ret, Abl, Abl (T315I), ALK, Aurora A, Bmx, CDK / cyclinE, Kit, Src, EGFR, EphA1, FGFR3, FLT3, Fms, IGF-1R, IKKb, IR, Itk, JAK2, KDR, Met, mTOR, PDGFRa, Plk1, Ret, Syk, Tie2, TrtB and the like. Therefore, research is underway to develop a target anticancer agent through the development of a compound having selective inhibitory activity against a specific kinase among various protein kinases.
- AML acute myeloid leukemia
- Fms3 Fms-Like tyrosine receptor kianse-3
- FLT3 FLT3 is one of the most frequently mutated genes in patients with acute myeloid leukemia. In about 25% of patients with AML, the FLT3 gene is mutated to FLT3-ITD, and the FLT3-ITD mutation is one of the major factors that make early diagnosis difficult.
- FLT3-ITD mutations point mutations (D835Y, D835V, D835F) of D835 amino acids in the activation loop have been reported. These mutations are found in about 10% of AML patients, making FLT3 unstable and inducing overactivity of FLT3.
- Overactive mutations such as FLT3-ITD, FLT3-D835 point mutations cause AML by continually increasing downstream signals associated with differentiation and proliferation of blood cells.
- AML-induced FLT3 mutations are becoming drug targets in the development of AML targeted therapies.
- New drug candidates targeting FLT3 that have been developed to date include Lestaurtinib, Sunitinib, Sorafenib, Quizartinib, and Tandutinib. The test has entered. However, the candidates are point mutations of FLT-ITD, and in particular, FLT3-ITD-F691L, FLT3-ITD-D835Y and the like have been reported to have a rapid decrease in activity. Therefore, there is an urgent need to develop a new compound having inhibitory activity against drug-resistant point mutations of FLT3 as a target therapeutic agent for acute myeloid leukemia (AML).
- AML acute myeloid leukemia
- Another object of the present invention is the treatment of a cancer disease containing a novel 2,3,5-substituted thiophene compound, a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof or an isomer thereof as an active ingredient, Its purpose is to provide a pharmaceutical composition useful for prevention and alleviation.
- Another object of the present invention is to provide a method for preparing the 2,3,5-substituted thiophene compound.
- the present invention is selected from the group consisting of 2,3,5-substituted thiophene compounds represented by the following formula (1), pharmaceutically acceptable salts thereof, hydrates thereof, solvates thereof and isomers thereof
- the compound is characterized by that.
- Z is O, S or NH
- Y is C 1- 6 alkylene group; C 2- 6 alkenylene group; Or is a 2- C 6 alkynylene group,
- N is 1 to 2 comprising a C 3- 8 hetero cyclo alkyl group; C 6- 12 aryl group; Or a C 3-12 heteroaryl group containing 1 to 2 heteroatoms selected from N or S,
- R 1 is halo, nitro, cyano, C 1- 6 alkyl, C 1- 6 haloalkyl, - (CH 2) m -C 1- 6 alkoxy (wherein, m is an integer from 1 to 6), -C ( O) OC 1- 6 alkyl, -S (O) 2 -C 1- 6 alkyl, C 3- 8 cyclo alkyl, containing from O or N heteroatom is 1 to 2 heteroatoms selected C 3- 8 cyclo alkyl, C 6-12 aryl, a substituent from the group consisting of 3- C 8 heteroaryl group containing 1 to 2 heteroatoms selected from O or N, the number of substitution of the substituent R 1 are numbered 0 to 3, the substituent R 1 is heteroaryl cyclo alkyl, aryl or heteroaryl, when is halo, C 1- 6 alkyl, C 1-6 alkyl, -C (O) - or C 1- 6 alkyl, -S (O) 2 - a substituted
- R 2 and R 3 are the same as or different from each other and are a hydrogen atom; Halogen atom; Hydroxyl group; C 1-6 alkyl group; C 3- 8 cyclo alkyl group; 1- C 6 hydroxyalkyl group; 1- C 6 haloalkyl group; C 1- 6 alkoxy group; -C (O) -C 1-6 alkyl group; -S (O) 2 -C 1- 6 alkyl group; Or -NR 4 R 5 ego,
- R 4 and R 5 are the same as or different from each other and are a hydrogen atom; C 1- 6 alkyl group; C 3- 8 cyclo alkyl group; Containing 1 to 2 heteroatoms selected from O N or C 3- 8 hetero cyclo alkyl group; Or a C 6- 12 aryl group,
- n is an integer of 1-3.
- 2,3,5-substituted thiophene compounds according to the invention are ANKK1, BLK, BUB1, CHEK1, CHEK2, CSF1R, CSK, DAPK1, PDGFRA, PDGFRB, PHKG1, SRC, YANK1, DRAK1, DRAK2, FGR, FLT3, FLT4, FYN, HCK, PRKG2, SYK, TAK1, IRAK1, IRAK4, JAK3, KIT, MAP3K2, MAP3K3, MAP4K2, MAP4K4, RET, RIPK4, TNIK, TRKA, TRKB, YSK4, MEK1, MEK2, MEK5, MERT
- MERT The ability to inhibit the activity of MKNK2, MLK1, MLK3, MST1, MST2, PAK4, PAK6, ULK1, ULK2 protein kinase is excellent. Therefore, it can be used for the treatment, prevention and alleviation of cancer diseases caused by abnormal cell growth.
- Cancer diseases that can be treated, prevented and alleviated from the compounds according to the invention include gastric cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, scleroderma, uterine cancer, cervical cancer, head and neck cancer , Esophageal cancer, thyroid cancer, parathyroid cancer, kidney cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, hematologic cancer (including leukemia, multiple myeloma, myelodysplastic syndrome), lymphoma (including Hochkin's disease, non-Hodgkin's lymphoma), psoriasis, or Fibroadenoma, and the like.
- gastric cancer including gastric cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, scleroderma, uterine cancer, cervical cancer, head and neck cancer , Es
- the 2,3,5-substituted thiophene compounds according to the present invention have the activity of inhibiting the proliferation of FLT3-ITD-bearing leukemia cell lines and Ba / F3 cell lines, as well as drug-resistant point mutations of FLT3 (F691L , D835Y, F691L / D835Y) also shows excellent inhibitory activity, which is effective in the treatment of acute myeloid leukemia.
- Pharmaceutically acceptable salts of the compounds represented by Formula 1 according to the present invention may be prepared by conventional methods in the art. Pharmaceutically acceptable salts are of low toxicity to humans and should not adversely affect the biological activity and physicochemical properties of the parent compound. Pharmaceutically acceptable salts include pharmaceutically usable free acids and acid addition salts of base compounds of formula (1), alkali metal salts (such as sodium salts) and alkaline earth metal salts (such as calcium salts), and organic salts and carboxyl compounds of formula (1). Organic base addition salts of acids and amino acid addition salts. Free acids that can be used for the preparation of pharmaceutically acceptable salts can be divided into inorganic acids and organic acids.
- the inorganic acid may be hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, bromic acid, or the like.
- Organic acids include acetic acid, methanesulfonic acid, ethanesulfonic acid, p -toluenesulfonic acid, trifluoroacetic acid, fumaric acid, maleic acid, malonic acid, phthalic acid, succinic acid, lactic acid, citric acid, citric acid, gluconic acid, tartaric acid, salicylic acid , Malic acid, oxalic acid, benzoic acid, embonic acid, aspartic acid, glutamic acid and the like can be used.
- Organic bases that can be used for the preparation of organic base addition salts are tris (hydroxymethyl) methylamine, dicyclohexylamine and the like.
- Amino acids that can be used to prepare amino acid addition bases are natural amino acids such as alanine, glycine and the like.
- the compound represented by Chemical Formula 1 according to the present invention includes all hydrates and solvates in addition to the pharmaceutically acceptable salts described above.
- the pharmaceutically acceptable salts described above may be prepared by conventional methods, for example, by dissolving the base compound of Formula 1 in a solvent which may be mixed with water such as methanol, ethanol, acetone, 1,4-dioxane, etc. It can then be prepared by adding free acid or free base followed by crystallization or recrystallization.
- the compound represented by Formula 1 according to the present invention may have one or more asymmetric centers, and in the case of such compounds, enantiomers or diastereomers may be present. Accordingly, the present invention includes each isomer or a mixture of these isomers. Different isomers can be separated or resolved by conventional methods, or any given isomer can be obtained by conventional synthesis or by stereospecific or asymmetric synthesis.
- the present invention includes a radioactive derivative of the compound represented by Formula 1 according to the present invention, these radioactive compounds are useful in the field of biological research.
- 'halo' or 'halogen atom' is a term that can be used interchangeably and means chloro, fluoro, bromo, and iodo.
- 'Alkyl' in the present invention has 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 4 carbon atoms, and refers to a linear, pulverized or cyclic aliphatic saturated hydrocarbon group. .
- alkyl groups include methyl group, ethyl group, normal propyl group, isopropyl group, cyclopropyl group, cyclopropylmethyl group, normal butyl group, isobutyl group, tert -butyl group, cyclobutyl group, normal pentyl group and iso Pentyl group, neopentyl group, tert -pentyl group, cyclopentyl group, normal hexyl group, isohexyl group, cyclohexyl group, normal heptyl group, normal octyl group and the like can be included.
- the "haloalkyl group” includes 1 to 13 halogen atoms such as fluoro, chloro, bromo and iodo, and includes both linear and pulverized carbon chains having 1 to 6 carbon atoms.
- haloalkyl group may include a fluoromethyl group, trifluoromethyl group, 1,2-dichloroethyl group, 1,1-dichloroethyl group, pentafluoroethyl group, and the like.
- Alkoxyalkyl in the present invention means an aliphatic saturated hydrocarbon group in which at least one alkoxy is bonded to the linear or pulverized carbon chain as defined above.
- alkoxyalkyl groups include methoxymethyl group, 2-methoxyethyl group, 2-ethoxyethyl group, 3-methoxypropyl group, 1-methoxy-isopropyl group, 2-methoxybutyl group, 4- A methoxybutyl group, 2-methyl-2- methoxypropyl group, etc. can be contained.
- Heterocycloalkyl' in the present invention means an aliphatic ring of 5 to 10, each containing 1 to 2 heteroatoms selected from O and N, saturated or partially saturated.
- a heterocycloalkyl group include tetrahydrofuranyl group, 2,3-dihydrofuranyl group, 2,5-dihydrofuranyl group, pyrrolidinyl group, 2,3-dihydropyrrolidinyl group, 2 , 5-dihydropyrrolidinyl group, tetrahydro- 2H -pyranyl group, 3,4-dihydro- 2H -pyranyl group, 4H -pyranyl group, piperidinyl group, 1,2,3,4 Tetrahydropyridinyl groups, 1,4-dihydropyridinyl groups, piperazinyl groups, N -protected piperazinyls, morpholino groups, and the like.
- the N -protecting group of piperazin
- 'aryl' means a monocyclic, bicyclic, or tricyclic aromatic hydrocarbon group having 6 to 12 carbon atoms.
- Specific examples of such an aryl group may include a phenyl group, a naphthalenyl group, and the like.
- Heteroaryl' in the present invention means an aromatic ring group containing 1 to 2 heteroatoms selected from S and N, and having 4 to 13 carbon atoms.
- Such heteroaryl is a thiophenyl group, a pyrronilyl group, a pyrazolyl group, an imidazolyl group, a thiazolyl group, an isothiazolyl group, a pyridinyl group, a pyrazinyl group, a pyridazinyl group, a pyrimidinyl group, an indolyl group, an isoindolinyl group, A zolnyl group, a benzimidazolyl group, a benzothiazolyl group, a benzisothiazolyl group, a quinolininyl group, an isoquinolinyl group, a phthalazinyl group, a quinazolinyl group, and the like can be included.
- Z is O, S or NH
- Y is C 1- 6 alkylene group; C 2- 6 alkenylene group; Or is a 2- C 6 alkynylene group,
- N is 1 to 2 comprising a C 3- 8 hetero cyclo alkyl group; C 6- 12 aryl group; Or a C 3-12 heteroaryl group containing 1 to 2 heteroatoms selected from N or S,
- R 1 is halo, nitro, cyano, C 1- 6 alkyl, C 1- 6 haloalkyl, - (CH 2) m -C 1- 6 alkoxy (wherein, m is an integer from 1 to 6), -C ( O) OC 1- 6 alkyl, -S (O) 2 -C 1- 6 alkyl, C 3- 8 cyclo alkyl, containing from O or N heteroatom is 1 to 2 heteroatoms selected C 3- 8 cyclo alkyl, C 6-12 aryl, a substituent from the group consisting of 3- C 8 heteroaryl group containing 1 to 2 heteroatoms selected from O or N, the number of substitution of the substituent R 1 are numbered 0 to 3, the substituent R 1 is heteroaryl cyclo alkyl, aryl or heteroaryl, when is halo, C 1- 6 alkyl, C 1-6 alkyl, -C (O) - or C 1- 6 alkyl, -S (O) 2 - a substituted
- R 2 and R 3 are the same as or different from each other and are a hydrogen atom; Halogen atom; Hydroxyl group; C 1-6 alkyl group; C 3- 8 cyclo alkyl group; 1- C 6 hydroxyalkyl group; 1- C 6 haloalkyl group; C 1- 6 alkoxy group; -C (O) -C 1-6 alkyl group; -S (O) 2 -C 1- 6 alkyl group; Or -NR 4 R 5 ego,
- R 4 and R 5 are the same as or different from each other and are a hydrogen atom; C 1- 6 alkyl group; C 3- 8 cyclo alkyl group; Containing 1 to 2 heteroatoms selected from O N or C 3- 8 hetero cyclo alkyl group; Or a C 6- 12 aryl group,
- n is an integer of 1-3.
- Y is C 1- 6 alkylene group; Or is a 2- C 6 alkynylene group,
- A is a piperidinyl group; Phenyl group; Thiophenyl group; Indazolyl group; Pyridinyl group; Pyrimidinyl group; Pyrazinyl group; Or a pyrazolyl group,
- R 1 is halo, nitro, cyano, C 1- 6 alkyl, C 1- 6 haloalkyl, -C (O) OC 1- 6 alkyl, -S (O) 2 -C 1-6 alkyl, - (CH 2) m -C 1- 6 alkoxy (wherein, m is an integer from 1 to 6), tetrahydro -2 H-pyran-carbonyl, piperidin dinnil, 4- (acetyl) -piperidin dinnil, 4- (C 1- 6 Alkylsulfonyl) -piperidinyl, pyrrolidinyl and morpholinyl, 0 to 3 substituents selected from the group consisting of:
- R 2 and R 3 are hydrogen atoms
- n is a compound which is an integer of 1-3.
- Z is O and Y is -CH 2 CH 2- ; Or -C ⁇ C-, R 2 and R 3 are hydrogen atoms, n is an integer from 1 to 3, and A is a phenyl group, R 1 is halo, nitro, cyano, methyl, ethyl, isopropyl, tri It is a compound which is 0 to 3 substituents selected from the group consisting of fluoromethyl, methoxycarbonyl and ethoxycarbonyl.
- Z is O and Y is -CH 2 CH 2- ; Or —C ⁇ C—, R 2 and R 3 are hydrogen atoms, n is an integer from 1 to 3, and A is a pyridinyl group, R 1 is halo, trifluoromethyl, methyl, ethyl, isopropyl, Compound having 0 to 2 substituents selected from the group consisting of pyrrolidinyl, piperidinyl and morpholino.
- Z is O and Y is -CH 2 CH 2- ; Or -C ⁇ C-, R 2 and R 3 are hydrogen atoms, n is an integer of 1 to 3, when A is a pyrimidinyl group, R 1 is 0 to 2 substituents selected from the group consisting of halo to be.
- Z is O and Y is -CH 2 CH 2- ; Or -C ⁇ C-, R 2 and R 3 are hydrogen atoms, n is an integer from 1 to 3, and A is a pyrazolyl group, R 1 is methyl, ethyl, isopropyl, methoxyethyl, ethoxyethyl , Tetrahydropyranyl, piperidinyl, 4-acetylpiperidinyl and 4-methylsulfonylpiperidinyl.
- Z is O and Y is -CH 2 CH 2- ; Or -C ⁇ C-, R 1 , R 2 and R 3 are hydrogen atoms, n is an integer from 1 to 3,
- A is a piperidinyl group; Phenyl group; Indazolyl group; Thiophenyl group; Pyrazolyl group; Pyrazinyl group; Pyridinyl group; Or a pyrimidinyl group.
- A is a piperidinyl group; Phenyl group; Thiophenyl group; Indazolyl group; Pyridinyl group; Pyrimidinyl group; Pyrazinyl group; Or a pyrazolyl group,
- R 1 is halo, nitro, cyano, C 1- 6 alkyl, C 1- 6 haloalkyl, -C (O) OC 1- 6 alkyl, -S (O) 2 -C 1-6 alkyl, - (CH 2) m -C 1- 6 alkoxy (wherein, m is an integer from 1 to 6), tetrahydro -2 H-pyran-carbonyl, piperidin dinnil, 4- (acetyl) -piperidin dinnil, 4- (C 1- 6 Alkylsulfonyl) -piperidinyl, pyrrolidinyl and morpholinyl, 0 to 3 substituents selected from the group consisting of:
- R 2 and R 3 are hydrogen atoms
- n is an integer of 1-3.
- the present invention is characterized by a method for producing a compound represented by the formula (1).
- the manufacturing method according to the present invention will be described in detail.
- the compound represented by Formula 1 may be prepared by performing the manufacturing process of 6 steps using the compound represented by Formula 2 as a starting material.
- R 1 , R 2 , A and n are as defined in Formula 1, respectively, X represents a halogen atom, TMS represents a trimethylsilyl group, and Boc represents a tert -butoxycarbonyl group.
- the one-step reaction is performed by reacting 2- (Boc-protected carboxamido) -3-amino-5-bromo-thiophene represented by Chemical Formula 2 with trimethylsilylacetylene represented by Chemical Formula 3 to form thiophene. Is the process of introducing an acetylene group to the C5 position.
- the one-step reaction is carried out by heating to a temperature of 50 ° C. to 90 ° C. under conditions in which triphenylphosphine palladium (Pd (PPh 3 ) 4 ) and copper iodide (CuI) are added and in the presence of an amine base.
- the amine base is mono-, di- or tri-C 1 ⁇ 6 may be selected from such as alkyl amines, preferably with triethylamine (TEA), diisopropyl use a trialkyl amine such as ethyl amine (DIPEA) Can be.
- TSA triethylamine
- DIPEA diisopropyl
- a conventional organic solvent may be used, and the examples of the present invention mainly dimethylformamide (DMF) are specifically illustrated, but the solvent of the present invention is not limited thereto.
- the two-step reaction is a process of detaching a trimethylsilyl (TMS) protecting group from the compound represented by Chemical Formula 4.
- TMS trimethylsilyl
- the two-step reaction is performed at room temperature using an inorganic base.
- the inorganic base may be selected from hydroxides, oxides, carbonates, sulfates, and the like of alkali metals or earth metals, and preferably carbonates of alkali metals such as potassium carbonate.
- the reaction solvent may be carried out under a mixed solvent of alcohol and tetrahydrofuran, and the alcohol may be representatively used as methanol or ethanol.
- the mixed solvent may be suitably mixed and used within a volume ratio of 1: 2 to 2: 1.
- the three-step reaction is a process of introducing the R group by reacting the compound represented by Chemical Formula 5 with the halide compound represented by Chemical Formula 6.
- the three step reaction is carried out by heating to a temperature of 70 ° C. to 120 ° C. under conditions in which triphenylphosphine palladium (Pd (PPh 3 ) 4 ) and copper iodide (CuI) are added and in the presence of an amine base.
- the amine base is mono-, di- or tri-C 1 ⁇ to 6 it may be selected from such as alkyl amines, and preferably may be a trialkylamine such as triethylamine, diisopropylethylamine.
- a conventional organic solvent may be used, and the examples of the present invention mainly dimethylformamide (DMF) are specifically illustrated, but the solvent of the present invention is not limited thereto.
- the four-step reaction is a process of introducing a urea group to the C3 position of thiophene by reacting the compound represented by Chemical Formula 7 with the compound represented by Chemical Formula 8.
- the four step reaction is performed at room temperature.
- Conventional organic solvents may be used as the reaction solvent, and examples of using tetrahydrofuran (THF) are specifically illustrated in Examples of the present invention, but the solvent of the present invention is not limited thereto.
- the 5-step reaction is a process of removing trichloroacetyl (F 3 CC (O) —) group from the compound represented by Chemical Formula 9.
- the five step reaction is performed at room temperature in the presence of an amine base.
- the amine base is mono-, di- or tri-C 1 ⁇ to 6 it may be selected from such as alkyl amines, and preferably may be a trialkylamine such as triethylamine, diisopropylethylamine.
- a reaction solvent a conventional organic solvent may be used, and the examples of the present invention specifically exemplify examples of using an alcohol solvent such as methanol, but the solvent of the present invention is not limited thereto.
- the six-step reaction is a process of detaching tert -butoxycarbonyl (Boc) group from the compound represented by Chemical Formula 10.
- the six step reaction is performed at room temperature using trifluoroacetic acid (TFA).
- TFA trifluoroacetic acid
- a conventional organic solvent may be used, and examples of the present invention mainly exemplify dichloromethane (MC), but the solvent of the present invention is not limited thereto.
- R 1 , R 2 , A and n are as defined in Formula 1, respectively, Boc represents a tert -butoxycarbonyl group.
- step A reaction is carried out by reacting 2- (Boc-protected carboxamido) -3-amino-5-bromo-thiophene represented by Chemical Formula 2 with an acetylene compound represented by Chemical Formula 11, It is the process of introducing an acetylene group to C5 position.
- the step A reaction is carried out by heating to a temperature of 60 ° C. to 120 ° C. under conditions in which triphenylphosphine palladium (Pd (PPh 3 ) 4 ) and copper iodide (CuI) are added and in the presence of an amine base.
- the amine base is mono-, di- or tri-C 1 ⁇ to 6 they may be selected from such as alkyl amines, and preferably may be a trialkylamine such as triethylamine, diisopropylethylamine.
- the reaction solvent a conventional organic solvent may be used, and the examples of the present invention mainly dimethylformamide (DMF) are specifically illustrated, but the solvent of the present invention is not limited thereto.
- the step B reaction is a process of introducing a urea group to the C3 position of thiophene by reacting the compound represented by Formula 7 with the compound represented by Formula 8.
- the step B reaction is performed at room temperature.
- Conventional organic solvents may be used as the reaction solvent, and examples of using tetrahydrofuran (THF) are specifically illustrated in Examples of the present invention, but the solvent of the present invention is not limited thereto.
- Step C reaction is a process of removing trichloroacetyl (F 3 CC (O) —) group from the compound represented by Formula 9.
- the step C reaction is performed at room temperature in the presence of an amine base.
- the amine base is mono-, di- or tri-C 1 ⁇ to 6 it may be selected from such as alkyl amines, and preferably may be a trialkylamine such as triethylamine, diisopropylethylamine.
- a reaction solvent a conventional organic solvent may be used, and the examples of the present invention specifically exemplify examples of using an alcohol solvent such as methanol, but the solvent of the present invention is not limited thereto.
- the step D reaction is a process of desorbing tert -butoxycarbonyl (Boc) from the compound represented by Chemical Formula 10.
- the step D reaction is carried out at room temperature using trifluoroacetic acid (TFA).
- TFA trifluoroacetic acid
- a conventional organic solvent may be used, and examples of the present invention mainly exemplify dichloromethane (MC), but the solvent of the present invention is not limited thereto.
- the reduction reaction according to Scheme 3 may be performed at room temperature while introducing hydrogen gas under a palladium (Pd) catalyst.
- a reaction solvent a conventional organic solvent may be used, and the examples of the present invention specifically exemplify examples of using an alcohol solvent such as methanol, but the solvent of the present invention is not limited thereto.
- Step a reaction is a process of nitrating the amine group of the thiophene compound represented by the formula (12).
- the step a reaction is performed at room temperature at -20 ° C to 0 ° C using sodium nitrate (NaNO 2 ), hydrochloric acid (HCl) and sodium tetrafluoroborate (NaBF 4 ), and water is used as a reaction solvent.
- NaNO 2 sodium nitrate
- HCl hydrochloric acid
- NaBF 4 sodium tetrafluoroborate
- a diazonium salt aqueous solution prepared by reacting copper and sodium nitrate is added to the reaction solution and reacted at room temperature, thereby preparing a thiophene compound represented by Chemical Formula 13 in which the nitro group is substituted.
- the step b reaction is a process of introducing a bromo atom into the C5 position of the thiophene compound represented by Chemical Formula 13.
- step b is reacted at room temperature using a bromination reagent such as N -bromosuccinimide, trifluoroacetic acid (TFA) and sulfuric acid.
- a bromination reagent such as N -bromosuccinimide, trifluoroacetic acid (TFA) and sulfuric acid.
- the c-step reaction is a process of hydrolyzing methoxycarbonyl (-COOMe) at the C1 position of the thiophene compound represented by Chemical Formula 14 to carboxylic acid (-COOH).
- the c step reaction proceeds at room temperature using an alkali metal hydroxide including sodium hydroxide.
- the reaction solvent may be carried out under a mixed solvent of alcohol and tetrahydrofuran, and the alcohol may be representatively used as methanol or ethanol.
- the mixed solvent may be suitably mixed and used within a volume ratio of 1: 2 to 2: 1.
- the d step reaction is a process of introducing an amido group at the C1 position of the thiophene by reacting the thiophene compound represented by Chemical Formula 15 with the amine compound represented by Chemical Formula 16.
- the d stage reaction is carried out with 1- [bis (dimethylamino) methylene] -1 H -1,2,3-triazolo [4,5- b ] pyridinium 3-oxide hexafluorophosphate (HATU) and amine It is performed at a temperature of 30 ° C. to 60 ° C. in the presence of a base.
- the amine base is mono-, di- or tri-C 1 ⁇ to 6 it may be selected from such as alkyl amines, and preferably may be a trialkylamine such as triethylamine, diisopropylethylamine.
- the reaction solvent a conventional organic solvent may be used, and the examples of the present invention mainly dimethylformamide (DMF) are specifically illustrated, but the solvent of the present invention is not limited thereto.
- Step e is a process of amination of the nit group of the C3 position of the thiophene compound represented by the formula (17).
- the step e reaction is performed at 30 ° C. to 60 ° C. using sodium nitrate (NaNO 2 ), hydrochloric acid (HCl) and sodium tetrafluoroborate (NaBF 4 ) using tin chloride (SnCl 2 ).
- a reaction solvent a conventional organic solvent may be used, and the examples of the present invention mainly exemplify ethyl acetate (EA), but the solvent of the present invention is not limited thereto.
- the f-step reaction is a process of protecting the amine group of the hetero ring in the C2 position in the thiophene compound represented by Formula 18.
- tert -butoxycarbonyl (Boc) is introduced as an amine protecting group. That is, the thiophene compound represented by Formula 17 is reacted with di- tert -butyl dicarbonate at room temperature in the presence of an amine base.
- the amine base is mono-, di- or tri-C 1 ⁇ to 6 it may be selected from such as alkyl amines, and preferably may be a trialkylamine such as triethylamine, diisopropylethylamine.
- a conventional organic solvent may be used as the reaction solvent, and examples of using dichloromethane (MC) are specifically illustrated in Examples of the present invention, but the solvent of the present invention is not limited thereto.
- the present invention includes a compound represented by the formula (1), pharmaceutically acceptable salts thereof, solvates thereof, hydrates thereof, the pharmaceutical composition for the treatment, prevention and alleviation of cancer diseases comprising the active ingredient.
- Cancer diseases that can be prevented and treated from the compounds according to the present invention are gastric cancer, lung cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, scleroderma, uterine cancer, cervical cancer, head and neck cancer, esophageal cancer , Thyroid cancer, parathyroid cancer, kidney cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, blood cancer (including leukemia, multiple myeloma, myelodysplastic syndrome), lymphoma (including Hochkin's disease, non-Hodgkin's lymphoma), psoriasis, or fibroadenoma Etc. may be included.
- the compound represented by Formula 1 inhibits the proliferation of FLT3-ITD-bearing leukemia cell lines and Ba / F3 cell lines, and at the same time, FLT3 point mutants such as gatekeeper mutants, D835 mutants, and ITD mutants. Excellent inhibitory activity. Therefore, it can be particularly useful as a prophylactic or therapeutic agent for acute myeloid leukemia.
- the pharmaceutical composition of the present invention contains a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, solvate thereof, or a hydrate thereof as an active ingredient, and includes a conventional nontoxic pharmaceutically acceptable carrier, adjuvant and excipient. And the like can be formulated into conventional formulations in the pharmaceutical field, for example, oral or parenteral formulations such as tablets, capsules, troches, solutions, suspensions and the like.
- Excipients that may be used in the pharmaceutical compositions of the present invention may include sweeteners, binders, solubilizers, solubilizers, wetting agents, emulsifiers, isotonic agents, adsorbents, disintegrants, antioxidants, preservatives, lubricants, fillers, fragrances and the like.
- lactose dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, silica, talc, stearic acid, sterin, magnesium stearate, magnesium aluminum silicate, starch, gelatin, tragacanth rubber, arginine acid, sodium Alginate, methyl cellulose, sodium carboxymethyl cellulose, agar, water, ethanol, polyethylene glycol, polyvinylpyrrolidone, sodium chloride, calcium chloride, orange essence, strawberry essence, vanilla flavor and the like.
- the dosage of the compound according to the present invention to the human body may vary depending on the age, weight, sex, dosage form, health condition and degree of disease of the patient, and is generally based on an adult patient having a weight of 70 kg. It is 0.01-1000 mg / day, and can be dividedly administered once a day to several times at regular time intervals according to the judgment of a doctor or a pharmacist.
- Elution solvent A 0.1% trifluoroacetic acid (TFA) / water
- Elution conditions elute for 7 minutes while changing the concentration of solvent B to 5-100% at a moving speed of 1.0 mL / min.
- Elution solvent A 0.1% trifluoroacetic acid (TFA) / water
- Elution condition Elution for 4.5 min with changing solvent B concentration to 5-100% at 1.2 mL / min moving speed.
- Elution solvent A 0.1% trifluoroacetic acid (TFA) / water
- Methyl 3-aminothiophen-2-carboxylate (15.7 g, 100 mmol) was added concentrated hydrochloric acid (26 mL, 842 mmol) to prepare a suspension, followed by addition of water (24 mL) and stirring at room temperature for 45 minutes. It was. After the reaction mixture was lowered to -10 ° C, a solution of sodium nitrate (NaNO 2 ; 7.2 g, 110 mmol) in water (16 mL) was slowly added thereto for 20 minutes. After the addition was complete, the reaction mixture was stirred at 0 ° C. for 1 hour, and a solution of sodium tetrafluoroborate (16 g, 150 mmol) in water (32 mL) was added thereto.
- the resulting salt was filtered, washed with cold 5% aqueous sodium tetrafluoroborate solution, ethanol, diethyl ether and dried. Then, activated copper powder (copper bronze, 16 g, 300 mmol) was added to a solution of sodium nitrate (NaNO 2 ; 80 g, 1160 mmol) in water (160 mL), followed by vigorous stirring and water (80 mL). After preparing a diazonium salt dissolved in, the reaction solution was slowly added at room temperature for 1 hour or more. After the addition was completed, the mixture was stirred for another 1 hour, diluted with ethyl acetate, and filtered through celite.
- activated copper powder (copper bronze, 16 g, 300 mmol) was added to a solution of sodium nitrate (NaNO 2 ; 80 g, 1160 mmol) in water (160 mL), followed by vigorous stirring and water (80 mL). After preparing a diazonium
- the organic layer was separated by separating the water layer and the organic layer, and the water layer was extracted again with ethyl acetate. The combined organic layers were dried over sodium sulfate, concentrated and purified by MPLC to give the title compound (15.1 g, 72%) as a white solid.
- Methyl 5-bromo-3-nitrothiophene-2-carboxylate (10 g, 37.6 mmol) was dissolved in a mixed solution of tetrahydrofuran / methanol (1: 1, 40 mL), and then 1N sodium hydroxide solution. (41.3 mL, 41.3 mmol) was added dropwise and stirred at room temperature for 1 hour. 2N aqueous hydrochloric acid solution was added to the reaction mixture, adjusted to pH 5, and extracted with ethyl acetate. The extracted organic layer was dried over magnesium sulfate and concentrated to give the title compound (8.0 g, 84%) as a gray solid.
- reaction mixture was extracted with ethyl acetate and saturated aqueous sodium bicarbonate solution to collect an organic layer.
- the combined organic layers were washed with brine, dried over sodium sulfate, concentrated under reduced pressure, and purified by MPLC to give the title compound (6.2 g, 80%) as a yellow solid.
- the reaction was cooled to room temperature and extracted with ethyl acetate and water to collect an organic layer.
- the combined organic layers were washed with brine, dried over sodium sulfate, concentrated under reduced pressure, and purified by MPLC to obtain the target compound (61.3 mg, 71.5%).
- the reaction was cooled to room temperature and extracted with ethyl acetate and water. The combined organic layers were washed with brine, dried over sodium sulfate, concentrated under reduced pressure, and purified by MPLC to obtain the target compound (3.0 g, 72%).
- the reaction was cooled to room temperature and extracted with ethyl acetate and water. The combined organic layers were washed with brine, dried over sodium sulfate, concentrated under reduced pressure, and purified by MPLC to obtain the target compound (173 mg, 95%).
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 38.
- the target compound was obtained by applying the method of Example 38.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 2.
- the target compound was obtained by applying the method of Example 51.
- the target compound was obtained by applying the method of Example 51.
- the target compound was obtained by applying the method of Example 51.
- the target compound was obtained by applying the method of Example 51.
- Table 1 shows the results of measuring the inhibitory effect of the kinase upon the treatment of 1 ⁇ M single concentration of the test compound.
- Ba / F3 cell lines expressing the FLT3 mutant gene were cultured in culture containing 90% RPMI, 10% FBS, and Welgene.
- Ba / F3 cell line was placed in a TC-treated 96-well plate (SPL), each of 5,000, 100 uL, and then diluted with dimethylsulfoxide (1 mM to 3 points, total 10 concentrations). uL was injected at a time. After 72 hours incubation in a cell culture incubator. 50 uL of Cell titer glo (Promega) solution was added and stored at room temperature for 10 minutes, and then the luminous intensity was measured using a reader (Envision, PerkinElmer). The luminescence intensity was plotted by the final concentration of the test compound, and the GI 50 value was determined using Prism 5.0 (GraphPad) software.
- Parental Ba / F3 cell lines without FLT3 mutant genes were cultured with mouse IL-3 (R & D Systems) at a final concentration of 1 ng / mL in culture containing 90% RPMI, 10% FBS, and Welgene. And incubated. Activity was measured in the same manner as above.
- Table 2 shows the results of measuring the growth inhibitory activity of each test compound against Parental Ba / F3, FLT3-ITD, FLT3-ITD-F691L, FLT3-D835Y, FLT3-ITD-F691L-D835Y cells.
- novel compound represented by Formula 1 according to the present invention can be formulated in various forms according to the purpose.
- the following illustrates some formulation methods containing the compound represented by Formula 1 according to the present invention as an active ingredient, but the present invention is not limited thereto.
- Injectables were prepared by containing 100 mg as the active ingredient, followed by 180 mg of mannitol, 26 mg of Na 2 HPO 4 .12H 2 O and 2974 mg of distilled water.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (9)
- 하기 화학식 1로 표시되는 2,3,5-치환된 싸이오펜 화합물, 이의 약학적으로 허용되는 염, 이의 수화물, 이의 용매화물 및 이의 이성질체로 이루어진 군으로부터 선택된 화합물 :[화학식 1]상기 화학식 1에서,Z는 O, S 또는 NH이고,Y는 C1- 6알킬렌기; C2- 6알케닐렌기; 또는 C2- 6알키닐렌기이고,A는 N가 1 내지 2개 포함된 C3- 8헤테로싸이클로알킬기; C6- 12아릴기; 또는 N 또는 S로부터 선택된 헤테로원자가 1 내지 2개 포함된 C3-12 헤테로아릴기이고,R1은 할로, 니트로, 시아노, C1- 6알킬, C1- 6할로알킬, -(CH2)m-C1- 6알콕시(이때, m은 1 내지 6의 정수), -C(O)O-C1- 6알킬, -S(O)2-C1- 6알킬, C3- 8싸이클로알킬, O 또는 N으로부터 선택된 헤테로원자가 1 내지 2개 포함된 C3- 8헤테로싸이클로알킬, C6- 12아릴, O 또는 N으로부터 선택된 헤테로원자가 1 내지 2개 포함된 C3- 8헤테로아릴로 이루어진 군으로부터 치환기이고, 상기 치환기 R1의 치환개수는 0 내지 3개이고, 상기 치환기 R1이 헤테로싸이클로알킬, 아릴 또는 헤테로아릴인 경우는 할로, C1- 6알킬, C1-6알킬-C(O)- 또는 C1- 6알킬-S(O)2-에 의해 치환 또는 비치환될 수 있고,R2 및 R3은 서로 같거나 다른 것으로서 수소원자; 할로겐원자; 하이드록시기; C1-6알킬기; C3- 8싸이클로알킬기; C1- 6하이드록시알킬기; C1- 6할로알킬기; C1- 6알콕시기; -C(O)-C1-6알킬기; -S(O)2-C1- 6알킬기; 또는 -NR4R5 이고,R4 및 R5는 서로 같거나 다른 것으로서 수소원자; C1- 6알킬기; C3- 8싸이클로알킬기; O 또는 N으로부터 선택된 헤테로원자가 1 내지 2개 포함된 C3- 8헤테로싸이클로알킬기; 또는 C6- 12아릴기이고,n은 1 내지 3의 정수이다.
- 제 1 항에 있어서,Z는 O이고,Y는 C1- 6알킬렌기; 또는 C2- 6알키닐렌기이고,A는 피페리딘닐기; 페닐기; 싸이오펜닐기; 인다졸닐기; 피리딘닐기; 피리미딘닐기; 피라진닐기; 또는 피라졸닐기이고,R1은 할로, 니트로, 시아노, C1- 6알킬, C1- 6할로알킬, -C(O)O-C1- 6알킬, -S(O)2-C1-6알킬, -(CH2)m-C1- 6알콕시(이때, m은 1 내지 6의 정수), 테트라하이드로-2H피란닐, 피페리딘닐, 4-(아세틸)-피페리딘닐, 4-(C1- 6알킬설포닐)-피페리딘닐, 피롤리딘닐 및 몰폴린닐로 이루어진 군으로부터 선택된 0 내지 3개의 치환기이고,R2 및 R3은 수소원자이고,n은 1 내지 3의 정수인 것을 특징으로 하는 화합물.
- 하기 화학식 1a로 표시되는 2,3,5-치환된 싸이오펜 화합물, 이의 약학적으로 허용되는 염, 이의 수화물, 이의 용매화물 및 이의 이성질체로 이루어진 군으로부터 선택된 화합물 :[화학식 1a]상기 화학식 1a에서,Z는 O이고,A는 피페리딘닐기; 페닐기; 싸이오펜닐기; 인다졸닐기; 피리딘닐기; 피리미딘닐기; 피라진닐기; 또는 피라졸닐기이고,R1은 할로, 니트로, 시아노, C1- 6알킬, C1- 6할로알킬, -C(O)O-C1- 6알킬, -S(O)2-C1-6알킬, -(CH2)m-C1- 6알콕시(이때, m은 1 내지 6의 정수), 테트라하이드로-2H피란닐, 피페리딘닐, 4-(아세틸)-피페리딘닐, 4-(C1- 6알킬설포닐)-피페리딘닐, 피롤리딘닐 및 몰폴린닐로 이루어진 군으로부터 선택된 0 내지 3개의 치환기이고,R2 및 R3은 수소원자이고,n은 1 내지 3의 정수인 것을 특징으로 하는 화합물.
- 제 1 항에 있어서,1) 에틸 (S)-4-((5-(피페리딘-3-닐카바모닐)-4-유레이도싸이오펜-2-닐)에티닐)벤조에이트;2) (S)-5-(페닐에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;3) (S)-N-(피페리딘-3-닐)-5-(피리딘-3-닐에티닐)-3-유레이도싸이오펜-2-카복스아마이드;4) (S)-N-(피페리딘-3-닐)-5-(피리딘-4-닐에티닐)-3-유레이도싸이오펜-2-카복스아마이드;5) (S)-5-((3-니트로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;6) (S)-5-((3-시아노페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;7) (S)-5-((4-니트로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;8) (S)-5-((4-클로로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;9) (S)-5-((4-플루오로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;10) (S)-N-(피페리딘-3-닐)-5-(피리딘-2-닐에티닐)-3-유레이도싸이오펜-2-카복스아마이드;11) (S)-5-((4-시아노페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;12) (S)-5-((1H-인다졸-3-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;13) (S)-5-((6-플루오로피리딘-3-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;14) (S)-5-((3,4-다이플루오로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;15) (S)-5-((1-메틸-1H-피라졸-4-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;16) (S)-N-(피페리딘-3-닐)-5-((4-(트리플루오로메틸)페닐)에티닐)-3-유레이도싸이오펜-2-카복스아마이드;17) (S)-N-(피페리딘-3-닐)-5-((6-(트리플루오로메틸)피리딘-3-닐)에티닐)-3-유레이도싸이오펜-2-카복스아마이드;18) 메틸 (S)-4-((5-(피페리딘-3-닐카바모일)-4-유레이도싸이오펜-2-닐)에티닐)벤조에이트;19) (S)-5-((6-클로로피리딘-3-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;20) (S)-5-((5-플루오로피리딘-3-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;21) (S)-5-((2-플루오로피리딘-4-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;22) (S)-5-((3-플루오로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;23) (S)-5-((1-(1-(메틸설포닐)피페리딘-4-닐)-1H-피라졸-4-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;24) (S)-N-(피페리딘-3-닐)-5-(p-토릴에티닐)-3-유레이도싸이오펜-2-카복스아마이드;25) (S)-5-((3-브로모-4-시아노페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;26) (S)-5-((4-시아노-3-플루오로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;27) (S)-5-((3-플루오로-4-(트리플루오로메틸)페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;28) (S)-5-((4-클로로-3-시아노페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;29) (S)-5-((2-클로로피리미딘-5-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;30) (S)-N-(피페리딘-3-닐)-5-(피라진-2-닐에티닐)-3-유레이도싸이오펜-2-카복스아마이드;31) (S)-5-((4-클로로-3-플루오로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;32) (S)-5-((3,5-다이플루오로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;33) (S)-5-((2-플루오로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;34) (S)-5-((2,3-다이플루오로페닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;35) (S)-5-((6-메틸피리딘-3-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;36) (S)-N-(피페리딘-3-닐)-5-((6-(피롤리딘-1-닐)피리딘-3-닐)에티닐)-3-유레이도싸이오펜-2-카복스아마이드;37) (S)-5-((6-(피페리딘-1-닐)피리딘-3-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;38) (S)-5-((6-몰폴리노피리딘-3-닐)에티닐)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;39) 5-((1-메틸-1H-피라졸-4-닐)에티닐)-N-(피롤리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;40) 5-((3-플루오로페닐)에티닐)-N-(피롤리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;41) (S)-N-(아제판-3-닐)-5-((1-메틸-1H-피라졸-4-닐)에티닐)-3-유레이도싸이오펜-2-카복스아마이드;42) (S)-5-((1H-피라졸-4-닐)에티닐)-N-(아제판-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;43) (S)-N-(아제판-3-닐)-5-((1-에틸-1H-피라졸-4-닐)에티닐)-3-유레이도싸이오펜-2-카복스아마이드;44) (S)-N-(아제판-3-닐)-5-((1-이소프로필-1H-피라졸-4-닐)에티닐)-3-유레이도싸이오펜-2-카복스아마이드;45) (S)-N-(아제판-3-닐)-5-((1-(2-메톡시에틸)-1H-피라졸-4-닐)에티닐)-3-유레이도싸이오펜-2-카복스아마이드;46) (S)-N-(아제판-3-닐)-5-((1-(테트라하이드로-2H-피란-4-닐)-1H-피라졸-4-닐)에티닐)-3-유레이도싸이오펜-2-카복스아마이드;47) (S)-N-(아제판-3-닐)-5-((1-(1-(메틸설포닐)피페리딘-4-닐)-1H-피라졸-4-닐)에티닐)-3-유레이도싸이오펜-2-카복스아마이드;48) (S)-N-(아제판-3-닐)-5-(싸이오펜-3-닐에티닐)-3-유레이도싸이오펜-2-카복스아마이드;49) (S)-5-((1-(1-아세틸피페리딘-4-닐)-1H-피라졸-4-닐)에티닐)-N-(아제판-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;50) (S)-N-(아제판-3-닐)-5-((3-플루오로페닐)에티닐)-3-유레이도싸이오펜-2-카복스아마이드;51) 5-(2-(1-메틸-1H-피라졸-4-닐)에틸)-N-(피롤리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;52) (S)-N-(아제판-3-닐)-5-(2-(1-메틸-1H-피라졸-4-닐)에틸)-3-유레이도싸이오펜-2-카복스아마이드;53) (S)-5-(3-플루오로펜에틸)-N-(피페리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;54) (S)-N-(아제판-3-닐)-5-(3-플루오로펜에틸)-3-유레이도싸이오펜-2-카복스아마이드; 또는55) 5-(3-플루오로펜에틸)-N-(피롤리딘-3-닐)-3-유레이도싸이오펜-2-카복스아마이드;로 이루어진 군으로부터 선택된 것을 특징으로 하는 화합물.
- 제 1 항 내지 제 4 항 중에서 선택된 어느 한 항의 화합물이 활성성분으로 포함되어 있는 암질환의 치료, 예방 및 경감용 약학적 조성물.
- 제 5 항에 있어서,상기 암질환은 위암, 폐암, 간암, 대장암, 소장암, 췌장암, 뇌암, 뼈암, 흑색종, 유방암, 경화성선증, 자궁암, 자궁경부암, 두경부암, 식도암, 갑상선암, 부갑상선암, 신장암, 육종, 전립선암, 요도암, 방광암, 혈액암, 림프종, 건선, 또는 섬유선종 중에서 선택된 것을 특징으로 하는 약학적 조성물.
- 제 1 항 내지 제 4 항 중에서 선택된 어느 한 항의 화합물이 활성성분으로 포함되어 있는 급성골수성백혈병의 치료, 예방 및 경감용 약학적 조성물.
- 하기의 제조과정을 포함하는 2,3,5-치환된 싸이오펜화합물의 제조방법:(1단계) 하기 화학식 2로 표시되는 2-(Boc보호된 카복스아미도)-3-아미노-5-브로모-싸이오펜과 하기 화학식 3으로 표시되는 트리메틸실릴 아세틸렌을 반응시켜, 싸이오펜의 C5 위치에 아세틸렌 그룹이 도입된 하기 화학식 4로 표시되는 화합물을 제조하는 과정;(상기 반응식에서, R2 및 n은 청구항 1에서 정의한 바와 같고, TMS는 트리메틸실릴기이고, Boc는 tert-부톡시카보닐기이다)(2단계) 하기 화학식 4로 표시되는 화합물로부터 트리메틸실릴(TMS) 보호기를 탈리시켜, 하기 화학식 5로 표시되는 화합물을 제조하는 과정;(상기 반응식에서, R2 및 n은 청구항 1에서 정의한 바와 같고, TMS는 트리메틸실릴기이고, Boc는 tert-부톡시카보닐기이다)(3단계) 하기 화학식 5로 표시되는 화합물과 하기 화학식 6으로 표시되는 할라이드 화합물을 반응시켜, 하기 화학식 7로 표시되는 화합물을 제조하는 과정;(상기 반응식에서, R1, R2, A 및 n은 청구항 1에서 정의한 바와 같고, X는 할로겐원자이고, TMS는 트리메틸실릴기이고, Boc는 tert-부톡시카보닐기이다)(4단계) 하기 화학식 7로 표시되는 화합물과 하기 화학식 8로 표시되는 트리클로로아세틸 이소시아네이트를 반응시켜, 하기 화학식 9로 표시되는 화합물을 제조하는 과정;(상기 반응식에서, Z, R1, R2, A 및 n은 청구항 1에서 정의한 바와 같고, Boc는 tert-부톡시카보닐기이다)(5단계) 하기 화학식 9로 표시되는 화합물로부터 트리클로로아세틸 (F3CC(O)-) 그룹을 제거하여, 하기 화학식 10으로 표시되는 화합물을 제조하는 과정; 및(상기 반응식에서, Z, R1, R2, A 및 n은 청구항 1에서 정의한 바와 같고, Boc는 tert-부톡시카보닐기이다)(6단계) 하기 화학식 10으로 표시되는 화합물로부터 tert-부톡시카보닐 (Boc) 그룹을 탈리시켜, 하기 화학식 1a로 표시되는 화합물을 제조하는 과정.(상기 반응식에서, Z, R1, R2, A 및 n은 청구항 1에서 정의한 바와 같고, Boc는 tert-부톡시카보닐기이다)
- 하기의 제조과정을 포함하는 2,3,5-치환된 싸이오펜화합물의 제조방법:(A단계) 하기 화학식 2로 표시되는 2-(Boc보호된 카복스아미도)-3-아미노-5-브로모-싸이오펜과 하기 화학식 11로 표시되는 아세틸렌 화합물을 반응시켜, 싸이오펜의 C5 위치에 아세틸렌 그룹이 도입된 하기 화학식 7로 표시되는 화합물을 제조하는 과정;(상기 반응식에서, R1, R2, A 및 n은 청구항 1에서 정의한 바와 같고, Boc는 tert-부톡시카보닐기이다)(B단계) 하기 화학식 7로 표시되는 화합물과 상기 화학식 8로 표시되는 트리클로로아세틸 이소시아네이트를 반응시켜, 하기 화학식 9로 표시되는 화합물을 제조하는과정;(상기 반응식에서, R1, R2, A 및 n은 청구항 1에서 정의한 바와 같고, Boc는 tert-부톡시카보닐기이다)(C단계) 하기 화학식 9로 표시되는 화합물로부터 트리클로로아세틸 (F3CC(O)-) 그룹을 제거하여, 하기 화학식 10으로 표시되는 화합물을 제조하는 과정; 및(상기 반응식에서, Z, R1, R2, A 및 n은 청구항 1에서 정의한 바와 같고, Boc는 tert-부톡시카보닐기이다)(D단계) 하기 화학식 10으로 표시되는 화합물로부터 tert-부톡시카보닐 (Boc) 그룹을 탈리시켜, 하기 화학식 1a로 표시되는 화합물을 제조하는 과정.(상기 반응식에서, Z, R1, R2, A 및 n은 청구항 1에서 정의한 바와 같고, Boc는 tert-부톡시카보닐기이다)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK17753486.4T DK3418275T3 (da) | 2016-02-16 | 2017-02-16 | Hidtil ukendt 2,3,5-substitueret thiophenforbindelse som proteinkinasehæmmer |
EP17753486.4A EP3418275B1 (en) | 2016-02-16 | 2017-02-16 | Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor |
NZ745210A NZ745210A (en) | 2016-02-16 | 2017-02-16 | Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor |
MX2018009861A MX2018009861A (es) | 2016-02-16 | 2017-02-16 | Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa. |
JP2018561463A JP6749422B2 (ja) | 2016-02-16 | 2017-02-16 | プロテインキナーゼ阻害剤である新規な2,3,5−置換チオフェン化合物 |
CN201780021441.1A CN108884066B (zh) | 2016-02-16 | 2017-02-16 | 作为蛋白激酶抑制剂的2,3,5-取代的噻吩化合物 |
BR112018016729-0A BR112018016729B1 (pt) | 2016-02-16 | 2017-02-16 | Novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase |
CA3014740A CA3014740C (en) | 2016-02-16 | 2017-02-16 | 2,3,5-substituted thiophene compound as protein kinase inhibitor |
AU2017221707A AU2017221707B2 (en) | 2016-02-16 | 2017-02-16 | Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor |
ES17753486T ES2866890T3 (es) | 2016-02-16 | 2017-02-16 | Nuevo compuesto de tiofeno 2,3,5-sustituido como inhibidor de la proteína cinasa |
RU2018130703A RU2724957C2 (ru) | 2016-02-16 | 2017-02-16 | Новое соединение 2,3,5-замещенного тиофена в качестве ингибитора протеинкиназы |
US15/998,791 US10442796B2 (en) | 2016-02-16 | 2018-08-16 | 2,3,5-substituted thiophene compound as protein kinase inhibitor |
HK19100430.7A HK1258053A1 (zh) | 2016-02-16 | 2019-01-11 | 作為蛋白激酶抑制劑的新的2,3,5-取代的噻吩化合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160017991 | 2016-02-16 | ||
KR10-2016-0017991 | 2016-02-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/998,791 Continuation-In-Part US10442796B2 (en) | 2016-02-16 | 2018-08-16 | 2,3,5-substituted thiophene compound as protein kinase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017142325A1 true WO2017142325A1 (ko) | 2017-08-24 |
Family
ID=59626142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/001715 WO2017142325A1 (ko) | 2016-02-16 | 2017-02-16 | 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 |
Country Status (16)
Country | Link |
---|---|
US (1) | US10442796B2 (ko) |
EP (1) | EP3418275B1 (ko) |
JP (2) | JP6749422B2 (ko) |
KR (3) | KR20170096599A (ko) |
CN (1) | CN108884066B (ko) |
AU (1) | AU2017221707B2 (ko) |
BR (1) | BR112018016729B1 (ko) |
CA (1) | CA3014740C (ko) |
DK (1) | DK3418275T3 (ko) |
ES (1) | ES2866890T3 (ko) |
HK (1) | HK1258053A1 (ko) |
MX (1) | MX2018009861A (ko) |
NZ (1) | NZ745210A (ko) |
PT (1) | PT3418275T (ko) |
RU (1) | RU2724957C2 (ko) |
WO (1) | WO2017142325A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112566915A (zh) * | 2018-08-13 | 2021-03-26 | 吉利德科学公司 | 噻二唑irak4抑制剂 |
US20210205290A1 (en) * | 2018-05-30 | 2021-07-08 | Pharos Ibio Co., Ltd. | Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers |
US20210205289A1 (en) * | 2018-05-30 | 2021-07-08 | Pharos Ibio Co., Ltd. | Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapy |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6749422B2 (ja) * | 2016-02-16 | 2020-09-02 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | プロテインキナーゼ阻害剤である新規な2,3,5−置換チオフェン化合物 |
CN110643672A (zh) * | 2019-10-15 | 2020-01-03 | 西安交通大学 | 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途 |
KR102578970B1 (ko) * | 2020-03-04 | 2023-09-15 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물의 난소암 예방, 개선 또는 치료 용도 |
US20230293507A1 (en) * | 2020-03-04 | 2023-09-21 | Pharos Ibio Co., Ltd | Use of 2,3,5-substituted thiophene compound for preventing, ameliorating, or treating ovarian cancer |
KR102535842B1 (ko) * | 2020-07-31 | 2023-05-23 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물의 비만세포증 예방, 개선 또는 치료 용도 |
KR102535840B1 (ko) * | 2020-07-31 | 2023-05-23 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도 |
WO2023063784A1 (ko) * | 2021-10-14 | 2023-04-20 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030095188A (ko) * | 2000-06-19 | 2003-12-18 | 파마시아 이탈리아 에스.피.에이. | 키나제 억제제로서 활성인 티오펜 유도체, 이의 제조방법및 이를 포함하는 약제학적 조성물 |
KR20050088283A (ko) * | 2002-10-30 | 2005-09-05 | 버텍스 파마슈티칼스 인코포레이티드 | Rock 및 기타 단백질 키나제의 억제제로서 유용한조성물 |
KR20060127127A (ko) * | 2004-01-05 | 2006-12-11 | 아스트라제네카 아베 | Chk 1 억제제로서 티오펜 유도체 |
KR100703622B1 (ko) * | 2005-10-26 | 2007-04-06 | 삼성전기주식회사 | 캡 방식의 카메라 모듈 |
US20090325925A1 (en) * | 2008-01-25 | 2009-12-31 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69434969T2 (de) * | 1993-07-15 | 2008-01-10 | Cancer Research Campaign Technology Ltd. | Verbindungen die zur herstellung von protein-tyrosin-kinase-inhibitor-prodrogen verwendet werden können |
JP2005064770A (ja) * | 2003-08-11 | 2005-03-10 | Ricoh Co Ltd | 情報処理装置、認証装置、外部装置、証明情報取得方法、認証方法、機能提供方法、証明情報取得プログラム、認証プログラム、機能提供プログラム及び記録媒体 |
US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
CA2561977A1 (en) * | 2004-03-30 | 2005-10-13 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
EP1893605A2 (en) * | 2005-03-31 | 2008-03-05 | AstraZeneca AB | Saminopyrimidine derivates with tie2 inhibiting activity |
CA2825367C (en) * | 2011-01-21 | 2018-09-25 | Sun Pharma Advanced Research Company Ltd. | Diarylacetylene hydrazide containing tyrosine kinase inhibitors |
JP6749422B2 (ja) * | 2016-02-16 | 2020-09-02 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | プロテインキナーゼ阻害剤である新規な2,3,5−置換チオフェン化合物 |
-
2017
- 2017-02-16 JP JP2018561463A patent/JP6749422B2/ja active Active
- 2017-02-16 ES ES17753486T patent/ES2866890T3/es active Active
- 2017-02-16 RU RU2018130703A patent/RU2724957C2/ru active
- 2017-02-16 BR BR112018016729-0A patent/BR112018016729B1/pt active IP Right Grant
- 2017-02-16 DK DK17753486.4T patent/DK3418275T3/da active
- 2017-02-16 CN CN201780021441.1A patent/CN108884066B/zh active Active
- 2017-02-16 NZ NZ745210A patent/NZ745210A/en unknown
- 2017-02-16 CA CA3014740A patent/CA3014740C/en active Active
- 2017-02-16 WO PCT/KR2017/001715 patent/WO2017142325A1/ko active Application Filing
- 2017-02-16 PT PT177534864T patent/PT3418275T/pt unknown
- 2017-02-16 EP EP17753486.4A patent/EP3418275B1/en active Active
- 2017-02-16 MX MX2018009861A patent/MX2018009861A/es unknown
- 2017-02-16 AU AU2017221707A patent/AU2017221707B2/en active Active
- 2017-02-16 KR KR1020170020896A patent/KR20170096599A/ko active Application Filing
-
2018
- 2018-08-16 US US15/998,791 patent/US10442796B2/en active Active
- 2018-12-17 KR KR1020180163545A patent/KR101965326B1/ko active Application Filing
-
2019
- 2019-01-11 HK HK19100430.7A patent/HK1258053A1/zh unknown
- 2019-03-27 KR KR1020190035405A patent/KR102069730B1/ko active IP Right Grant
-
2020
- 2020-05-20 JP JP2020088146A patent/JP2020143118A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030095188A (ko) * | 2000-06-19 | 2003-12-18 | 파마시아 이탈리아 에스.피.에이. | 키나제 억제제로서 활성인 티오펜 유도체, 이의 제조방법및 이를 포함하는 약제학적 조성물 |
KR20050088283A (ko) * | 2002-10-30 | 2005-09-05 | 버텍스 파마슈티칼스 인코포레이티드 | Rock 및 기타 단백질 키나제의 억제제로서 유용한조성물 |
KR20060127127A (ko) * | 2004-01-05 | 2006-12-11 | 아스트라제네카 아베 | Chk 1 억제제로서 티오펜 유도체 |
KR100703622B1 (ko) * | 2005-10-26 | 2007-04-06 | 삼성전기주식회사 | 캡 방식의 카메라 모듈 |
US20090325925A1 (en) * | 2008-01-25 | 2009-12-31 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210205290A1 (en) * | 2018-05-30 | 2021-07-08 | Pharos Ibio Co., Ltd. | Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers |
US20210205289A1 (en) * | 2018-05-30 | 2021-07-08 | Pharos Ibio Co., Ltd. | Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapy |
JP2021525284A (ja) * | 2018-05-30 | 2021-09-24 | ファロス・アイバイオ・カンパニー・リミテッド | 2,3,5−置換されたチオフェン化合物の乳癌の予防、改善または治療用途 |
JP2021525285A (ja) * | 2018-05-30 | 2021-09-24 | ファロス・アイバイオ・カンパニー・リミテッド | 2,3,5−置換されたチオフェン化合物の放射線治療増進用途 |
JP7041322B2 (ja) | 2018-05-30 | 2022-03-23 | ファロス・アイバイオ・カンパニー・リミテッド | 2,3,5-置換されたチオフェン化合物の乳癌の予防、改善または治療用途 |
EP3804719A4 (en) * | 2018-05-30 | 2022-03-30 | Pharos Ibio Co., Ltd. | USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND TO IMPROVE RADIATION THERAPY |
JP7098054B2 (ja) | 2018-05-30 | 2022-07-08 | ファロス・アイバイオ・カンパニー・リミテッド | 2,3,5-置換されたチオフェン化合物の放射線治療増進用途 |
US11938123B2 (en) | 2018-05-30 | 2024-03-26 | Pharos Ibio Co., Ltd. | Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers |
CN112566915A (zh) * | 2018-08-13 | 2021-03-26 | 吉利德科学公司 | 噻二唑irak4抑制剂 |
CN112566915B (zh) * | 2018-08-13 | 2024-04-09 | 吉利德科学公司 | 噻二唑irak4抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
MX2018009861A (es) | 2019-06-06 |
HK1258053A1 (zh) | 2019-11-01 |
KR101965326B1 (ko) | 2019-04-03 |
PT3418275T (pt) | 2021-04-22 |
ES2866890T3 (es) | 2021-10-20 |
CA3014740C (en) | 2021-06-01 |
US20190047993A1 (en) | 2019-02-14 |
CA3014740A1 (en) | 2017-08-24 |
JP6749422B2 (ja) | 2020-09-02 |
BR112018016729B1 (pt) | 2023-10-24 |
KR20190035671A (ko) | 2019-04-03 |
RU2018130703A (ru) | 2020-03-17 |
NZ745210A (en) | 2019-08-30 |
AU2017221707A1 (en) | 2018-08-30 |
JP2019504900A (ja) | 2019-02-21 |
DK3418275T3 (da) | 2021-05-10 |
EP3418275A4 (en) | 2019-07-17 |
BR112018016729A2 (pt) | 2018-12-26 |
KR20170096599A (ko) | 2017-08-24 |
EP3418275A1 (en) | 2018-12-26 |
AU2017221707B2 (en) | 2019-10-03 |
CN108884066A (zh) | 2018-11-23 |
JP2020143118A (ja) | 2020-09-10 |
KR102069730B1 (ko) | 2020-01-23 |
RU2018130703A3 (ko) | 2020-03-17 |
KR20180136425A (ko) | 2018-12-24 |
US10442796B2 (en) | 2019-10-15 |
RU2724957C2 (ru) | 2020-06-29 |
EP3418275B1 (en) | 2021-03-17 |
CN108884066B (zh) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017142325A1 (ko) | 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 | |
WO2017026718A1 (ko) | Ret 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-디]피리미딘-4-아민 화합물 | |
WO2016085221A2 (ko) | 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체 | |
WO2020171606A1 (ko) | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 | |
WO2017188694A1 (ko) | 질소를 포함하는 헤테로아릴 화합물 및 이의 용도 | |
WO2018139903A1 (ko) | 피리미딘 화합물 및 그의 의약 용도 | |
WO2022055181A1 (ko) | Egfr 돌연변이 암의 억제용 화합물 및 이들의 의약 용도 | |
WO2019112269A1 (ko) | Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체 | |
EP2906558A1 (en) | Sodium channel blockers, preparation method thereof and use thereof | |
WO2018155947A1 (ko) | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 | |
WO2014109530A1 (ko) | 2-(페닐에티닐)티에노[3,4-b]피라진 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2016032209A2 (ko) | 야누스인산화효소 억제제로서의 치환된 n-(피롤리딘-3-일)-7h-피롤로[2,3-d]피리미딘-4-아민 | |
EP3681877A1 (en) | Pyrazole derivative compound and use thereof | |
WO2017034245A1 (ko) | 야누스 키나제 1 선택적 억제제 및 그 의약 용도 | |
WO2021096112A1 (ko) | 피롤로피리미딘, 피롤로피리딘, 인다졸 화합물 유도체 및 이를 포함하는 치료용 약학 조성물 | |
WO2010032986A2 (ko) | 신규 5-(4-아미노페닐)-이소퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 | |
WO2021172871A1 (ko) | 단백질 인산화 효소 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도 | |
WO2018139883A1 (ko) | 다중 표적 키나아제 저해제로서 융합피리미딘 유도체 | |
WO2022139304A1 (ko) | Sos1 억제제로서의 신규한 퀴나졸린 유도체 화합물 및 이의 용도 | |
WO2017164705A1 (ko) | 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물 | |
AU2019344240B2 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
WO2021040422A1 (ko) | 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체 | |
WO2021112626A1 (ko) | 신규한 인디루빈 유도체 및 이의 용도 | |
WO2021137665A1 (ko) | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도 | |
WO2019198940A1 (ko) | 우수한 카이네이즈 저해 활성을 보이는 다양한 치환기를 갖는 피리미딘 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17753486 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/009861 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2018561463 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3014740 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018016729 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017221707 Country of ref document: AU Date of ref document: 20170216 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017753486 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017753486 Country of ref document: EP Effective date: 20180917 |
|
ENP | Entry into the national phase |
Ref document number: 112018016729 Country of ref document: BR Kind code of ref document: A2 Effective date: 20180816 |